Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil's effectiveness is questioned due to unconvincing clinical trial and lack of FDA approval.
Microneedling is considered an important addition to hair loss treatments like Finasteride, Minoxidil, and Nizoral, with evidence suggesting it enhances Minoxidil's effectiveness and can improve hair growth on its own. Users discuss various microneedling techniques, including heavy weekly sessions and lighter daily sessions, while expressing concerns about potential scalp damage and discomfort.
User fought hair loss with Derminator microneedling, topical and oral minoxidil, and a 2000 FUE hair transplant. Derminator was a game changer, preventing further loss.
Microneedling aftercare involves using saline water instead of sea water, and avoiding hyaluronic acid due to its potential pro-inflammatory effects. Users suggest using jojoba oil as a carrier for essential oils like rosemary and lavender, and combining microneedling with minoxidil for better hair regrowth results.
The user plans to dermaroll and use minoxidil for hair loss over the next 4 months, documenting progress monthly. They will also consider finasteride later and include vitamins, a custom shampoo, castor oil, scalp massages, and increased water intake in their regimen.
Microneedling may worsen hair loss due to potential scarring and inflammation, with some users suggesting caution and proper technique to avoid damage. Alternatives like Minoxidil, finasteride, and RU58841 are implied as safer options.
The conversation discusses hair loss treatments, specifically using topical finasteride and minoxidil combined with microneedling, along with supplements like collagen, vitamin C/D, and saw palmetto. The user also mentions using a DHT-blocking shampoo and experimenting with cold showers and contrast therapy for hair health.
The user has been using finasteride 1.2mg daily, topical minoxidil 1ml daily, tretinoin with topical minoxidil 1ml every other day, and a 1.5mm derma roller every two weeks for 8 months to treat hair loss. The user has posted progress pictures over time.
An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.
The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.
The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.
Microneedling on the vertex may require trimming hair to ensure needles reach the scalp effectively. Using a needle length of 1.0–1.5 mm is suggested, and longer hair might get damaged if not cut.
Microneedling combined with minoxidil is more effective for hair growth than microneedling alone. Optimal results are seen with weekly microneedling using 0.5 - 1mm needles and regular minoxidil application, avoiding minoxidil on the needled area for 24 hours.
The user successfully reduced hair loss using pumpkin seed oil, Nizoral shampoo, and astaxanthin without using minoxidil or finasteride. They observed significant improvement over 12 months and believe the combination of treatments is effective.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
A user has been using oral finasteride and minoxidil without significant hair regrowth and is questioning the effectiveness of adding microneedling to their routine. Another user suggests microneedling can help with topical treatments but doesn't see it as a major factor in improving hair loss.
A 51-year-old shared their hair recovery journey using finasteride, minoxidil, and dermarolling, noting significant improvement in hairline and temple areas. They emphasize consistency and patience, while another user suggests adding topical kx-826 and melatonin for additional benefits.
The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.
A 19-year-old is concerned about long-term microneedling for hair loss and is unsure if it will remain effective as they age. They experienced side effects from topical finasteride and are considering whether to try it again in the future, while also dealing with body dysmorphia and stress.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
The post discusses allergens in everyday shampoos and skincare products, listing yearly allergens from 2000 to 2023. It suggests that these chemicals might contribute to acne and hair loss.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
A user shared impressive hair growth results after 77 days using oral finasteride, topical minoxidil, and weekly microneedling. They reported thicker, darker hair and minimal shedding, with treatment costs around 30 euros per month.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The user has been using minoxidil and finasteride for hair loss but is now considering microneedling due to recent hairline regression. Another user reassures that derma rolling causes only slight redness, which usually heals overnight.